Novartis’ heart failure med Entresto scores an expanded approval in the US
Extended indication in chronic heart failure authorised by the FDA
Read More
Tag: Entresto
Novartis announces positive results from two Entresto trials
Heart failure is a chronic and progressive condition, which impacts 26 million people worldwide.
Read More
Timely use of Novartis’ Entresto could save thousands of lives
Timely and broad adoption of Novartis’ Entresto by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than 28,000 deaths each year in the US alone, finds a new analysis published in JAMA Cardiology.
Read More
Global guidelines back Novartis’ heart drug Entresto
Novartis’ ‘breakthrough’ therapy Entresto has received a strong endorsement in updated EU and US guidelines on the treatment of heart failure.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
